GlycoVaxyn is formerly owned by Sofinnova Partners, through Sofinnova Capital VII, since 2012.

When did Sofinnova Partners acquire GlycoVaxyn?

Sofinnova Partners acquired GlycoVaxyn in 2012 and exited after 3 years.

Has GlycoVaxyn been sold?

Yes. GlycoVaxyn was exited in 2015 via Trade Sale.

Home/Companies/Biotech/GlycoVaxyn

GlycoVaxyn

Biotech·

Switzerland·Exited 2015·Held 3yr

GlycoVaxyn is a healthcare / biotech company, headquartered in Switzerland.

Entry

2012

Hold

3yr

Exit

2015

Est. EV

–

Investor

Sofinnova Partners

Key facts

HQSwitzerland

SectorHealthcare / Biotech

Swiss company developing bio-conjugate vaccines against severe bacterial infections using its in vivo glycosylation platform, acquired by…Read full notes

See the full ownership history.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Full fund context: vintage, strategy, region

Exit details: type, year, MOIC (buyer on Pro)

Start free

Already a member? Sign in

More from Sofinnova Capital VII

Other portfolio companies in the same fund.

Advanced Perfusion Diagnostics

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Last updated April 2026 · Sourced from public filings